ÜBER DIESE EPISODE
While artificial intelligence is expected to transform biopharmaceutical manufacturing, many manufacturers still face challenges in adopting these technologies at scale. Fragmented data, disconnected manufacturing systems and differences in how information is shared across organizations are creating barriers to AI adoption, raising questions about what manufacturers need to prioritize before investing in more advanced tools.
In this episode of Off Script, we spoke with Justin Byers, founder and CEO of Axio BioPharma, about some of the findings from the company's report, AI in Biomanufacturing: The 2026–2029 Outlook. The conversation explored the gap between AI ambitions and the reality of manufacturing facilities, the importance of building a strong data foundation, and how digital twins could support more advanced biomanufacturing processes. Byers also discussed the challenges of sharing manufacturing data across industry partners, the evolving regulatory expectations around AI in GMP environments, and how AI and digital technologies could reshape biologics manufacturing in the coming years.
